BioLineRx (BLRX) Total Non-Current Liabilities (2012 - 2025)

BioLineRx's Total Non-Current Liabilities history runs 14 years deep, the most recent figure standing at $5.4 million for Q4 2025.

• In Q4 2025, Total Non-Current Liabilities fell 45.84% year-over-year to $5.4 million; the TTM figure through Dec 2025 stood at $5.4 million (down 45.84% YoY), while the FY2025 annual figure was $5.4 million, down 45.84% from the prior year.
• Total Non-Current Liabilities was $5.4 million for Q4 2025 at BioLineRx, down from $6.6 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $25.4 million in Q2 2023 to a low of $1.6 million in Q2 2022.
• Historically, Total Non-Current Liabilities has averaged $11.2 million across 5 years, with a median of $8.3 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities tumbled 78.22% in 2022, then surged 1452.87% in 2023.
• A 5-year view of Total Non-Current Liabilities shows it stood at $3.6 million in 2021, then surged by 314.62% to $14.9 million in 2022, then tumbled by 46.73% to $7.9 million in 2023, then increased by 26.79% to $10.0 million in 2024, then plunged by 45.84% to $5.4 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $5.4 million (Q4 2025), $6.6 million (Q3 2025), and $7.7 million (Q2 2025), per Business Quant data.